Dayvigo Dosage/Direction for Use

Dosing Information: The recommended dosage of DAYVIGO is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability. Time to sleep onset may be delayed if taken with or soon after a meal [see Pharmacology: Pharmacokinetics under Actions].
DAYVIGO should be used at the lowest dose and for the shortest duration as clinically indicated.
Dosage Recommendations for Concomitant Use with CYP3A Inhibitors or CYP3A Inducers: Co-administration with Strong or Moderate CYP3A Inhibitors: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors [see Interactions, Pharmacology: Pharmacokinetics under Actions].
Co-administration with Weak CYP3A Inhibitors: The maximum recommended dosage of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors [see Interactions, Pharmacology: Pharmacokinetics under Actions].
Co-administration with Strong or Moderate CYP3A Inducers: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inducers [see Interactions, Pharmacology: Pharmacokinetics under Actions].
Dosage Recommendations for Patients with Hepatic Impairment: The maximum recommended dose of DAYVIGO is 5 mg no more than once per night in patients with moderate hepatic impairment [see Hepatic Impairment under Precautions, Pharmacology: Pharmacokinetics under Actions].
DAYVIGO is not recommended in patients with severe hepatic impairment [see Hepatic Impairment under Precautions].